Magenta Therapeutics share price today

(DNTH)

Magenta Therapeutics share price is $23.8 & ₹2,022.43 as on 21 Dec 2024, 2.30 'hrs' IST

$23.8

▲

0.76

(3.3%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Magenta Therapeutics share price in Dollar and Rupees. Guide to invest in Magenta Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Magenta Therapeutics. Get details on the Indian mutual funds that are investing in Magenta Therapeutics. Get Analyst recommendations and forecasts along with all the Magenta Therapeutics's financials.

Magenta Therapeutics share price movements

Today's Low: $22.52
Today's High: $24.21
$23.80
5.38%
Downside
Day's Volatility :6.98%
Upside
1.69%
52 Weeks Low: $8.24
52 Weeks High: $33.77
$23.80
65.39%
Downside
52 Weeks Volatility :75.61%
Upside
29.52%

Magenta Therapeutics Returns

Period	Magenta Therapeutics Inc	Index (Russel 2000)
3 Months	-9.06%	0.0%
6 Months	-6.74%	0.0%
1 Year	106.96%	0.0%
3 Years	366.67%	-19.7%

Magenta Therapeutics Key Statistics

in dollars & INR

Previous Close	$23.04
Open	$22.79
Today's High	$24.21
Today's Low	$22.52
Market Capitalization	$681.9M
Today's Volume	$381.1K
52 Week High	$33.77
52 Week Low	$8.2371
Revenue TTM	$5.4M
EBITDA	$-82.8M
Earnings Per Share (EPS)	$7.22
PE Ratio	3.19
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-25.99%

How to invest in Magenta Therapeutics from India?

It is very easy for Indian residents to invest directly in Magenta Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Magenta Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Magenta Therapeutics or DNTH on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Magenta Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Magenta Therapeutics shares which would translate to 0.036 fractional shares of Magenta Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Magenta Therapeutics, in just a few clicks!

Returns in Magenta Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Magenta Therapeutics investment value today

Current value as on today

₹2,09,153

Returns

₹1,09,153

(+109.15%)

Returns from Magenta Therapeutics Stock

₹1,06,957 (+106.96%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Magenta Therapeutics

-67%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Magenta Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -67% less investors are searching Magenta Therapeutics in the last 30 days versus the previous period.

Analyst Recommendation on Magenta Therapeutics

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Magenta Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Magenta Therapeutics

What analysts predicted

Upside of 117.65%

Current:

$23.80

Target:

$51.80

Insights on Magenta Therapeutics

Price Movement
In the last 3 years, DNTH stock has moved up by 370.4%
Increasing Revenue
Revenue is up for the last 4 quarters, 457.0K → 2.17M (in $), with an average increase of 38.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -10.56M → -25.17M (in $), with an average decrease of 33.7% per quarter

Magenta Therapeutics Financials in INR & Dollars

	FY21	Y/Y Change
Revenue	$1.5M	-
Net Income	$-13.1M	↓ 82.51%
Net Profit Margin	-888.14%	-

	FY22	Y/Y Change
Revenue	$6.4M	↑ 334.76%
Net Income	$-28.5M	↑ 117.22%
Net Profit Margin	-443.76%	↑ 444.38%

	FY23	Y/Y Change
Revenue	$2.8M	↓ 55.96%
Net Income	$-43.6M	↑ 52.95%
Net Profit Margin	-1.5K%	↓ 1097.46%

	Q2 FY23	Q/Q Change
Revenue	$969.0K	↑ 103.57%
Net Income	$-3.3M	↓ 88.74%
Net Profit Margin	-338.91%	↑ 5789.24%

	Q3 FY23	Q/Q Change
Revenue	$924.0K	↓ 4.64%
Net Income	$-14.8M	↑ 349.54%
Net Profit Margin	-1.6K%	↓ 1258.82%

	Q4 FY23	Q/Q Change
Revenue	$457.0K	↓ 50.54%
Net Income	$-10.6M	↓ 28.45%
Net Profit Margin	-2.3K%	↓ 713.65%

	Q1 FY24	Q/Q Change
Revenue	$874.0K	↑ 91.25%
Net Income	$-13.7M	↑ 30.15%
Net Profit Margin	-1.6K%	↑ 738.38%

	Q2 FY24	Q/Q Change
Revenue	$1.9M	↑ 113.16%
Net Income	$-17.6M	↑ 28.07%
Net Profit Margin	-945.09%	↑ 627.91%

	Q3 FY24	Q/Q Change
Revenue	$2.2M	↑ 16.59%
Net Income	$-25.2M	↑ 42.98%
Net Profit Margin	-1.2K%	↓ 213.93%

	FY18	Y/Y Change
Profit	$-875.0K	↑ 132.71%

	FY19	Y/Y Change
Profit	$-1.8M	↑ 110.63%

	FY20	Y/Y Change
Profit	$-2.0M	↑ 7.33%

	FY21	Y/Y Change
Profit	$-544.0K	↓ 72.5%

	FY22	Y/Y Change
Profit	$6.3M	↓ 1252.57%

	FY23	Y/Y Change
Profit	$2.5M	↓ 60.59%

	Q2 FY23	Q/Q Change
Profit	$969.0K	↓ 232.56%

	Q3 FY23	Q/Q Change
Profit	$905.0K	↓ 6.6%

	Q4 FY23	Q/Q Change
Profit	$354.0K	↓ 60.88%

	Q1 FY24	Q/Q Change
Profit	$767.0K	↑ 116.67%

	Q2 FY24	Q/Q Change
Profit	$1.8M	↑ 128.42%

	Q3 FY24	Q/Q Change
Profit	$2.2M	↑ 23.97%

	FY21	Y/Y Change
Operating Cash Flow	$-9.9M	↓ 84.53%
Investing Cash Flow	$-33.0K	-
Financing Cash Flow	$14.9M	↓ 77.99%

	FY22	Y/Y Change
Operating Cash Flow	$-29.1M	↑ 193.52%
Investing Cash Flow	$-59.8M	↑ 181169.7%
Financing Cash Flow	$96.7M	↑ 548.31%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.5M	↓ 67.21%
Investing Cash Flow	$21.9M	↑ 20.59%
Financing Cash Flow	$0.0	↓ 100.0%

Magenta Therapeutics Technicals Summary

Sell

Neutral

Buy

Magenta Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Magenta Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Magenta Therapeutics Inc	6.54%	-6.74%	106.96%	366.67%	50.73%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.38%	12.23%	86.41%
Biontech Se	4.48%	30.56%	7.97%	-55.71%	237.85%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.37%	26.29%	108.55%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-2.55%	77.79%	80.12%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Magenta Therapeutics Inc	3.19	3.19	NA	0.0	-0.26	-0.19	NA	11.51
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Magenta Therapeutics Inc	Buy	$681.9M	50.73%	3.19	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	86.41%	17.51	33.61%
Biontech Se	Buy	$26.7B	237.85%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	108.55%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.12%	32.84	-4.51%

About Magenta Therapeutics

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Organization	Magenta Therapeutics
Employees	53
CEO	Mr. Marino Garcia M.B.A.
Industry	Miscellaneous

Management People of Magenta Therapeutics

Name	Title
Mr. Marino Garcia M.B.A.	President, CEO & Director
Mr. Ryan Savitz	Chief Financial Officer & Chief Business Officer
Mr. Simrat Randhawa M.B.A., M.D.	Chief Medical Officer
Mr. Edward G. Carr	Chief Accounting Officer
Mr. Judson Taylor	Head of Technical Operations
Dr. Jeffrey Stavenhagen Ph.D.	Chief Scientific Officer
Ms. Jennifer Davis Ruff	VP and Head of Investor Relations & Corporate Affairs.
Mr. Adam M. Veness Esq.	Senior VP, General Counsel & Secretary
Ms. Kristina Maximenko	Chief People Officer
Ms. Rashieda Gluck	Head of Clinical Development Operations

Important FAQs about investing in Magenta Therapeutics from India :

What is Magenta Therapeutics share price today?

Magenta Therapeutics share price today stands at $23.80, Open: $22.79 ; Previous Close: $23.04 ; High: $24.21 ; Low: $22.52 ; 52 Week High: $33.77 ; 52 Week Low: $8.24. The stock opens at $22.79, after a previous close of $23.04. The stock reached a daily high of $24.21 and a low of $22.52, with a 52-week high of $33.77 and a 52-week low of $8.24.

Can Indians buy Magenta Therapeutics shares?

Yes, Indians can invest in the Magenta Therapeutics (DNTH) from India.

With INDmoney, you can buy Magenta Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Magenta Therapeutics at zero transaction cost.

How can I buy Magenta Therapeutics shares from India?

It is very easy to buy Magenta Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Magenta Therapeutics be purchased?

Yes, you can buy fractional shares of Magenta Therapeutics with INDmoney app.

What are the documents required to start investing in Magenta Therapeutics stocks?

To start investing in Magenta Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.